Published: 3 December 2020
Publications
Recent approvals: new active ingredients or new indications
Published: 3 December 2020
Prescriber Update 41(4): 78
December 2020
For the period 16 July 2020 to 15 October 2020.
Recent approvals of medicines with new active ingredients
| Trade name (active ingredient) | Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Cabometyx (cabozantinib) | Tablet 20 mg 40 mg 60 mg |
Renal cell carcinoma |
| Carglumic Acid Waymade (carglumic acid) | Tablet 200 mg |
Hyperammonaemia |
| Emgality (galcanezumab) | Solution for injection 120 mg/mL prefilled pen 120 mg/mL prefilled syringe |
Migraine |
| Faslodex (fulvestrant) | Solution for injection 250 mg/5 mL |
Breast cancer |
| Fycompa (perampanel) | Tablet 2 mg 4 mg 6 mg 8 mg 10 mg 12 mg |
Epilepsy |
| Monofer (ferric derisomaltose) | Solution for injection 100 mg/mL 200 mg/2 mL 500 mg/5 mL 1000 mg/10 mL |
Iron deficiency |
| Prevymis (letermovir) | Tablet 240 mg 480 mg Concentrate for infusion 240 mg/12 mL 480 mg/24 mL |
Cytomegalovirus infection |
Approved medicines with new indications
| Trade Name (active ingredient) | Dose form and strength(s) | New therapeutic area(s) |
|---|---|---|
| Forxiga (dapagliflozin) | Tablet 10 mg |
Heart failure (in both diabetic and non-diabetic patients) |
| Imfinzi (durvalumab) | Concentrate for infusion 120 mg/2.4 mL 500 mg/10 mL |
Small cell lung cancer |
| Lucentis (ranibizumab) | Solution for injection 10 mg/mL |
Diabetic retinopathy |
| Soliris (eculizumab) | Solution for infusion 300 mg/30 mL |
Haemolytic uraemic syndrome |
| Spravato (esketamine) | Nasal solution 140 mg/mL |
Major depressive disorder |
| Tecentriq (atezolizumab) | Concentrate for infusion 1200 mg/20 mL |
Hepatocellular carcinoma |
| Venclexta (venetoclax) | Tablet 10 mg 50 mg 100 mg 10 mg, 50 mg, 100 mg combination pack |
Acute myeloid leukaemia |
- See the Medsafe website for more information about these medicines.
- Data sheets of currently marketed medicines are also available.
